Immunologic responses to antifibrotic treatment in IPF patients.
Sign Up to like & getrecommendations! Published in 2021 at "International immunopharmacology"
DOI: 10.1016/j.intimp.2021.107525
Abstract: BACKGROUND Idiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial lung disease limited to the lungs. Immunological dysregulation may significantly participate in the pathophysiology of IPF. The immunological responses to nintedanib therapy in IPF patients… read more here.
Keywords: antifibrotic treatment; treatment ipf; cell percentages; ipf patients ... See more keywords